Halberd Continues In-Vitro Successes With Elimination of Protein Linked to Depression

Rhea-AI Summary

Halberd Corporation (OTC PINK:HALB) announced successful in vitro elimination of C-Reactive Protein (CRP) from cerebral spinal fluid using tuned laser light. This follows their success in targeting ten antigens associated with PTSD and neurodegenerative diseases. With major depression affecting 21 million Americans, Halberd aims to develop a process to lower CRP levels linked to clinical depression. CEO William Hartman highlighted ongoing laboratory experimentation, upcoming animal tests, and plans for commercialization of their findings.

Positive

• Successful in vitro elimination of CRP linked to clinical depression.
• Prior success in eliminating ten antigens related to PTSD and neurodegenerative diseases.
• Plans to commercialize laboratory findings with a focus on animal testing.

Negative

• None.

JACKSON CENTER, PA / ACCESSWIRE / April 4, 2022 / Halberd Corporation (OTC PINK:HALB) demonstrated the extracorporeal elimination of C-Reactive Protein from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro. Halberd, encouraged by its recent success in eliminating all ten of the top antigens associated with PTSD (Post Traumatic Stress Disorder), CTE (Chronic Traumatic Encephalopathy) and numerous other neurodegenerative diseases, expanded their research to address elimination of the disease antigen associated with clinical depression - C-Reactive Protein^[1]. According to the National Institute of Mental Health, "Major depression is one of the most common mental disorders in the United States."^[2] An estimated 21 million Americans experienced at least one major depression episode in 2020. This represents about 8.4% of the population.

In the recent past, scientists, now part of Halberd, worked with the military to attempt to stem the rash of suicides associated with clinical depression due to PTSD/TBI.

Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "In patients with major clinical depression, numerous peer reviewed medical studies have shown increased levels of CRP, IL-6, IL-1 and TNF-alpha. These findings have also been corroborated by meta-analysis studies. Lowering the CSF level of these specific target antigens should greatly improve the clinical state of patients with PTSD and suicidal ideation. Halberd's in-vitro laboratory tests have achieved that long sought-after goal!"

William A. Hartman, Halberd's Chairman, President & CEO added, "Halberd's achievements in the entire neurodegenerative disease project have been truly historic! It is estimated that almost 40 million Americans are currently suffering some form of neurodegenerative disease. We have developed a step-by-step plan to convert our laboratory successes into a commercial product/process. There are certain business developments pending which could expedite these plans. In the interim, we will continue our laboratory experimentation on blood serum and plasma and then move forward with animal testing. We expect to announce some very exciting developments in that regard in the next several weeks."

To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC

About Halberd Corporation.
Halberd Corporation (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed twenty related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Company cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Company undertakes no obligation to revise these statements following the date of this news release.

[1]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3741070/

[2]https://www.nimh.nih.gov/health/statistics/major-depression

SOURCE: Halberd Corporation

View source version on accesswire.com:
https://www.accesswire.com/695791/Halberd-Continues-In-Vitro-Successes-With-Elimination-of-Protein-Linked-to-Depression

FAQ

What recent achievement did Halberd Corporation (HALB) announce regarding clinical depression?

Halberd Corporation announced the successful in vitro elimination of C-Reactive Protein from cerebral spinal fluid using tuned laser light.

How many Americans were estimated to experience major depression in 2020?

An estimated 21 million Americans experienced at least one episode of major depression in 2020.

What future plans does Halberd Corporation have following their recent success?

Halberd plans to continue laboratory experimentation, move forward with animal testing, and aims to commercialize their findings.

What is C-Reactive Protein (CRP) and its relevance to Halberd's research?

C-Reactive Protein is linked to clinical depression, and Halberd's research focuses on its elimination to improve clinical outcomes for patients.